Dendritic cell therapy is a personalized form of cancer immunotherapy that uses a patient's own immune cells to help recognize and attack cancer cells. This article explains how dendritic cell therapy works, who may be eligible, the treatment process in Germany, potential benefits and side effects, treatment costs, and how it is integrated into personalized cancer care at specialized German centers.

Dendritic Cell Therapy: An Advanced Immunotherapy for Cancer Treatment in Germany

Most cancer treatments attack the tumor directly. Dendritic cell therapy takes a different route: it teaches the patient's own immune system to find and destroy cancer cells. This makes it one of the most personalized forms of cancer immunotherapy in Germany, with each vaccine prepared specifically for the individual patient using their own immune cells.

Germany offers specialized laboratories and experienced multidisciplinary cancer centers that provide dendritic cell therapy for selected patients. For many international patients, it offers an additional treatment option that may be considered alongside standard cancer treatments rather than replacing them.
Dendritic cell therapy is a personalized form of immunotherapy that should be considered within a comprehensive cancer treatment plan rather than as a replacement for established therapies. A detailed medical evaluation helps determine whether the treatment is appropriate based on the patient's cancer type, stage, previous treatments and overall health making dendritic cell therapy a personalized form of cellular immunotherapy.

Patients considering dendritic cell therapy in Germany often want to understand how the treatment works, which cancers it has been studied for, and what current clinical evidence shows. TIG GmbH supports international patients from the initial medical review through treatment coordination and follow-up.

What Is Dendritic Cell Therapy?

Dendritic cell therapy in Germany is a form of personalized cellular immunotherapy that uses a patient's own immune cells to help recognize and fight cancer. It is also known as dendritic cell immunotherapy or dendritic cell vaccine therapy and belongs to the broader field of cancer vaccine therapy. The treatment is available at specialized centers for selected patients [2].

What Are Dendritic Cells?

Dendritic cells are specialized immune cells that act as messengers of the immune system by capturing abnormal cells and presenting them to T-cells, which coordinate the body's immune response. Dendritic cells are potent antigen-presenting cells, meaning they capture fragments of tumor cells and display them to T-cells, the immune cells that carry out the attack [4].

Dendritic cells were first described by Ralph Steinman in 1973. His pioneering research earned him a share of the 2011 Nobel Prize in Physiology or Medicine and laid the foundation for the development of dendritic cell vaccines [1].

How Does Dendritic Cell Therapy Work?

Dendritic cell cancer treatment involves several carefully controlled laboratory and clinical steps that help the immune system recognize and respond to cancer cells. In most protocols, peripheral blood monocytes are collected by leukapheresis and differentiated ex vivo into dendritic cells using cytokines such as GM-CSF and IL-4. A patient's dendritic cells are cultured outside the body, loaded with tumor antigens, matured in the laboratory, and then infused back into the patient [2].

Once returned, the matured cells travel to the lymph nodes and present the tumor targets to T-cells. Cross-presenting dendritic cells induce CD8 cytotoxic T-lymphocytes, which then seek out and destroy cancer cells carrying those markers [5]. This is the mechanism behind dendritic cell therapy for cancer.

Why is Dendritic Cell Therapy a Personalized Cancer Immunotherapy?

Because each vaccine is prepared using the patient's own immune cells and tumor-associated antigens, every treatment is individualized although vaccine preparation methods differ among clinical protocols. This is why dendritic cell therapy is considered a form of autologous, personalized cancer immunotherapy [2].

Unlike conventional medicines, each dendritic cell vaccine is prepared specifically for one patient using their own immune cells and tumor-related antigens. This personalized approach is one of the key features of immune-based cancer therapy in Germany.

Which Cancers Can Be Treated with Dendritic Cell Therapy in Germany?

Dendritic cell vaccines have been studied across a wide range of cancers. In one review of clinical trials published up to December 2021, twenty-five studies spanned thirteen different cancer types. The most common was melanoma, followed by glioblastoma and glioma, prostate, ovarian, and pancreatic cancer [3].

Findings come from separate trials in different cancers and patient groups, and are not directly comparable.Source: References [3], [6], [7], [8], [9], and [10].

Dendritic Cell Therapy for Brain Tumors, Lung Cancer, and Breast Cancer

Brain tumors have been a major focus. In a phase 3 trial, the DCVax-L dendritic cell vaccine was added to standard care in newly diagnosed glioblastoma, and median overall survival for the 331 patients in the intent-to-treat group was 23.1 months from surgery [8].

In lung cancer, a dendritic cell vaccine combined with carboplatin and pemetrexed chemotherapy was well tolerated in advanced disease, with a two-year survival rate of 52.57% [7]. For breast cancer, dendritic cell approaches are studied as a way to evoke an active immune response within the tumor [10].

Dendritic Cell Therapy for Gastrointestinal and Urological Cancers

Gastrointestinal cancers show some of the clearest signals. After surgery to remove colon cancer liver metastases, patients who received a dendritic cell vaccine had a median disease-free survival of 25.26 months, compared with 9.53 months for those under observation alone [6].

Pancreatic cancer has also been investigated in several clinical studies evaluating dendritic cell vaccines [3]. Among urological cancers, prostate cancer is the field's landmark: sipuleucel-T, an autologous dendritic cell vaccine, was approved by the FDA for metastatic prostate cancer and prolonged overall survival [9]. Kidney and liver cancers are also areas of ongoing study.

Dendritic Cell Therapy for Melanoma and Other Advanced Cancers

Melanoma is the most frequently studied cancer in dendritic cell vaccine trials, in part because it responds well to immune-based treatment, and ovarian cancer is another common indication in published research [3].

In patients with advanced or stage 4 cancer, dendritic cell therapy in Germany is generally considered alongside standard cancer treatments rather than as a replacement. Whether it is appropriate depends on the cancer type, disease stage, previous treatments, and a specialist's assessment. 

Eligibility for Dendritic Cell Therapy in Germany

Eligibility for dendritic cell therapy in Germany depends on a thorough review of the patient's cancer type, disease stage, prior treatments, and overall immune health. Specialized cancer centers evaluate these individual factors to determine if personalized immunotherapy is appropriate.

Who Is Suitable for Dendritic Cell Therapy

Eligibility is confirmed by a specialist after reviewing the diagnosis, imaging, and pathology. Suitable candidates generally include:

• Patients with advanced, recurrent, or metastatic cancer seeking an immune-based addition to standard care.
• Those whose cancer type has been studied in dendritic cell trials, such as melanoma, glioblastoma, lung, colon or prostate cancer [3].
• Patients with a good performance status who are expected to tolerate treatment and potentially benefit from an immune response.
• Those who wish to combine the therapy with chemotherapy, radiation or checkpoint inhibitors [5].

Who May Not Be Eligible for Dendritic Cell Therapy?

Some patients are not suitable candidates. These include people with severe immune deficiencies, uncontrolled infections or a general health status too fragile to allow an immune response to build.

The effectiveness of dendritic cell therapy may also be influenced by the tumor microenvironment, which can suppress immune activity and reduce the ability of dendritic cells to trigger an effective anti-tumor response [4]. A specialist assessment helps determine whether the treatment is suitable and what outcomes can realistically be expected.

How Is Dendritic Cell Therapy Performed in Germany?

Dendritic cell therapy in Germany follows a step-by-step treatment process that begins with a medical assessment and continues through vaccine preparation, administration, and follow-up care.

Blood Cell Collection and Dendritic Cell Vaccine Preparation

The treatment begins with the collection of the patient's immune cells through a blood collection procedure. In the laboratory, dendritic cells are isolated, cultured, loaded with tumor-associated antigens and matured into a personalized vaccine before being administered back to the patient [2].

This laboratory stage is a critical part of the treatment process. Before the vaccine is administered, quality control procedures help ensure that the prepared cells meet the required standards for clinical use.

How Is Dendritic Cell Therapy Administered?

The finished vaccine is administered by injection or infusion, depending on the treatment protocol. The activated dendritic cells then travel to the lymph nodes, where they help stimulate T-cells to recognize and attack cancer cells [2]. The procedure is quick, requires no surgery, and most patients continue their normal daily activities during the course.

Follow-Up and Monitoring After Dendritic Cell Therapy

Because immune responses build over time, response is judged over months rather than days. In selected cases, immune-related laboratory markers may also be evaluated as part of treatment monitoring [5].

For international patients, this monitoring is coordinated so it continues smoothly after they return home.

What Are the Benefits of Dendritic Cell Therapy in Germany?

Dendritic cell therapy offers a personalized, low-toxicity approach to cancer treatment in Germany. Designed to train the patient’s own immune system, this therapy provides key biological advantages when integrated alongside established treatments like chemotherapy and radiation.

Personalized Immune-Based Cancer Treatment

One of the main advantage of dendritic cell therapy is its personalized approach. Because the vaccine is prepared from the patient's own immune cells and tumor-associated antigens, it is designed specifically for that individual's cancer [2].

Another important advantage is its favorable safety profile. Across published clinical trials, dendritic cell vaccines have generally been well tolerated, with most reported side effects being mild to moderate [3]. This allows the therapy to be considered alongside standard cancer treatments in appropriately selected patients.

Combining Dendritic Cell Therapy with Standard Cancer Treatments

Dendritic cell therapy is designed to complement, not replace, established treatment. It is scheduled around surgery, chemotherapy, radiation and targeted therapy within a wider plan. Combination with chemotherapy, radiotherapy, immune checkpoint inhibitors or other systemic therapies may be considered when supported by the underlying disease, available evidence, and treating specialists.

One of the most active areas of research is combining dendritic cell therapy with immune checkpoint inhibitors. Dendritic cells prime T-cells, while checkpoint inhibitors release the brakes on those same T-cells, so the two are biologically complementary [5]. Evidence from lung cancer also shows the vaccine can be safely given alongside chemotherapy [7].

TIG GmbH arranges the specialist review that determines how dendritic cell immunotherapy in Germany should be sequenced with a patient's existing treatment.

How Effective Is Dendritic Cell Therapy for Cancer?

The effectiveness of dendritic cell therapy varies according to the cancer type, disease stage and whether it is combined with other treatments. The following results summarize findings reported in published clinical studies.

Figures come from separate trials in different cancers and patient groups. They are shown for context, not as direct comparisons.

Why Treatment Results May Vary Between Patients

The clearest results have come in specific settings: longer disease-free survival after colon cancer liver metastasis surgery, extended overall survival when added to standard glioblastoma care, and prolonged survival with the FDA-approved prostate cancer vaccine [6] [8] [9].

Response is shaped by the cancer type, the stage of disease, the patient's immune status, and whether the therapy is combined with other treatments. The strongest signals appear when it is added to standard care rather than used alone [5].

Clinical Studies of Dendritic Cell Therapy

Yes. Clinical studies have shown that dendritic cell therapy can stimulate anti-tumor immune responses, although the strength of evidence varies between different cancer types. The landmark is sipuleucel-T, the first dendritic cell vaccine approved by the FDA, which prolonged overall survival in metastatic prostate cancer in selected patients with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer [9]. Beyond that, randomized and phase 3 trials have reported meaningful results in colon cancer liver metastases and glioblastoma [6], [8].

Ongoing Research on Dendritic Cell Therapy in Germany

Research on dendritic cell therapy continues to expand, although the overall evidence is still evolving. In the review of twenty-five published dendritic cell trials, only one was a phase III study; the rest were phase I or phase II, designed mainly to establish safety and early signals of benefit [3].

Although early- and mid-stage clinical trials have shown encouraging results, larger randomized studies and long-term follow-up are still needed to better define the role of dendritic cell therapy in routine cancer care.

Regulatory Status and Treatment Availability in Germany

One dendritic cell vaccine, sipuleucel-T, has been formally approved for prostate cancer [9]. Most other dendritic cell therapies remain investigational and are offered as individualized treatment at specialized centers rather than as licensed, routine medicines.

Dendritic cell therapy in Germany is available at selected specialized centers under medical supervision and is generally offered alongside established cancer treatments when appropriate. Patients should discuss the potential benefits, limitations, and current evidence with their treating specialist before making treatment decisions.

What Are the Risks and Side Effects of Dendritic Cell Therapy?

The safety record is one of the therapy's strongest features. Across published trials, dendritic cell vaccines were well tolerated, with mostly mild-to-moderate grade 1 to 2 adverse effects [3]. The most commonly reported are:

• Flu-like symptoms, such as a low-grade fever.
• Fatigue.
• Mild skin reactions or rashes, sometimes at the injection site.

Serious reactions are uncommon. In the phase 3 glioblastoma trial, only 2.1% of patients experienced a grade 3 or 4 adverse event related to the vaccine [8].

Why Choose Germany for Dendritic Cell Therapy?

Preparing an autologous vaccine demands specialized laboratories with strict quality control, since the product is manufactured from the patient's own cells. Germany's facilities are equipped for exactly this kind of precise cell processing [2].

Its centers also combine molecular diagnostics, standard oncology and immune-based treatment in one system. Germany is home to several university hospitals and cancer centers with expertise in oncology, immunotherapy and clinical research, including:

TIG GmbH works with such centers and can connect each patient to the right immunotherapy specialist in Germany for their cancer.

Cost of Dendritic Cell Therapy in Germany

One provider offering dendritic cell therapy is Prof. Gansauge at LDG Laboratories.

What Does the Cost of Dendritic Cell Therapy Include?

The dendritic cell therapy cost in Germany generally covers the laboratory preparation of the personalized vaccine, the scheduled injections, and the associated assessment and monitoring. Because the vaccine is custom-made from the patient's own cells, laboratory processing is the largest single component [2].

Factors Affecting the Cost of Dendritic Cell Therapy

Several individual variables influence the overall cost of dendritic cell therapy in Germany. Treating medical teams evaluate factors such as the specific diagnosis, required vaccine dosage, and complementary treatments to determine an exact, transparent price quote prior to care.

• Cancer Type: Total costs vary depending on the specific type and stage of cancer being treated.
• Number of Injections: The overall expense depends on the number of vaccine doses required for the treatment course.
• Combination Therapies: Costs change if the therapy is combined with other treatments, such as chemotherapy or checkpoint inhibitors.
• Additional Medical Care: Required imaging, laboratory monitoring, and supportive care contribute to the final price.

TIG GmbH provides a transparent, personalized breakdown before treatment begins, so patients know exactly what to expect with no hidden fees.

International Patient Services for Dendritic Cell Therapy in Germany

For international patients, receiving cancer treatment in Germany involves more than the medical procedure itself and often requires coordinated travel, communication, and follow-up support:

• Medical report review, so specialists can advise on suitability before any travel.
• Medical visa assistance, including the documentation and invitation letters required.
• Interpreter support, so language is never a barrier to understanding the treatment.
• Treatment coordination, aligning appointments, laboratory scheduling, and follow-up.

This structured support removes the barriers that can otherwise complicate treatment abroad, letting patients focus on their care.

Why Choose TIG for Dendritic Cell Therapy in Germany?

TIG GmbH helps international patients approach dendritic cell immunotherapy in Germany with clarity and coordinated support at every stage. The service is informational and organizational, working alongside the treating specialists rather than replacing medical advice. From the first medical report review to specialist matching, scheduling, travel, and follow-up, the aim is to make a complex journey as smooth as possible, so patients can concentrate on their treatment and recovery.

Your Treatment Journey for Dendritic Cell Therapy in Germany

For patients ready to explore this option, the pathway is organized into clear stages:

• Medical report review, so specialists can advise before any travel.
• Specialist consultation, to confirm suitability and plan the approach.
• Blood collection, from a simple blood sample.
• Laboratory preparation, where the personalized vaccine is produced.
• Vaccine administration, given as scheduled injections.
• Follow-up and monitoring, continued after returning home.

Patients who want to book dendritic cell therapy consultation in Germany can start with a medical report review, and TIG GmbH coordinates each step from there.

References

1. Randolph G. J. (2021). Dendritic cells: The first step. The Journal of experimental medicine, 218(3), e20202077. 

2. Elwakeel, A., Bridgewater, H. E., & Bennett, J. (2023). Unlocking Dendritic Cell-Based Vaccine Efficacy through Genetic Modulation-How Soon Is Now?. Genes, 14(12), 2118. 

3. Laureano, R. S., Sprooten, J., Vanmeerbeerk, I., Borras, D. M., Govaerts, J., Naulaerts, S., Berneman, Z. N., Beuselinck, B., Bol, K. F., Borst, J., Coosemans, A., Datsi, A., Fučíková, J., Kinget, L., Neyns, B., Schreibelt, G., Smits, E., Sorg, R. V., Spisek, R., Thielemans, K., … Garg, A. D. (2022). Trial watch: Dendritic cell (DC)-based immunotherapy for cancer. Oncoimmunology, 11(1), 2096363. 

4. Clayton, G., Toffoli, E. C., de Gruijl, T. D., & van Kooyk, Y. (2025). Dendritic cell immunotherapy advances for solid tumors: Vaccination and modulation. Cell reports. Medicine, 6(11), 102412. 

5. Matsuo, K., Yoshie, O., Kitahata, K., Kamei, M., Hara, Y., & Nakayama, T. (2021). Recent Progress in Dendritic Cell-Based Cancer Immunotherapy. Cancers, 13(10), 2495. 

6. Rodriguez, J., Castañón, E., Perez-Gracia, J. L., Rodriguez, I., Viudez, A., Alfaro, C., Oñate, C., Perez, G., Rotellar, F., Inogés, S., López-Diaz de Cerio, A., Resano, L., Ponz-Sarvise, M., Rodriguez-Ruiz, M. E., Chopitea, A., Vera, R., & Melero, I. (2018). A randomized phase II clinical trial of dendritic cell vaccination following complete resection of colon cancer liver metastasis. Journal for immunotherapy of cancer, 6(1), 96. 

7. Zhong, R., Ling, X., Cao, S., Xu, J., Zhang, B., Zhang, X., Wang, H., Han, B., & Zhong, H. (2022). Safety and efficacy of dendritic cell-based immunotherapy (DCVAC/LuCa) combined with carboplatin/pemetrexed for patients with advanced non-squamous non-small-cell lung cancer without oncogenic drivers. ESMO open, 7(1), 100334. 

8. Liau, L. M., Ashkan, K., Tran, D. D., Campian, J. L., Trusheim, J. E., Cobbs, C. S., Heth, J. A., Salacz, M., Taylor, S., D'Andre, S. D., Iwamoto, F. M., Dropcho, E. J., Moshel, Y. A., Walter, K. A., Pillainayagam, C. P., Aiken, R., Chaudhary, R., Goldlust, S. A., Bota, D. A., Duic, P., … Bosch, M. L. (2018). First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma. Journal of translational medicine, 16(1), 142. 

9. Jähnisch, H., Füssel, S., Kiessling, A., Wehner, R., Zastrow, S., Bachmann, M., Rieber, E. P., Wirth, M. P., & Schmitz, M. (2010). Dendritic cell-based immunotherapy for prostate cancer. Clinical & developmental immunology, 2010, 517493. 

10. Hosseini, M., Seyedpour, S., Khodaei, B., Loghman, A. H., Seyedpour, N., Yazdi, M. H., & Rezaei, N. (2023). Cancer Vaccines for Triple-Negative Breast Cancer: A Systematic Review. Vaccines, 11(1), 146. 

Why Patients Worldwide Prefer Our Medical Services in Germany – Key Benefits Explained